Candel Therapeutics, Inc. — Director's Dealing 2021

Jul 27, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Candel Therapeutics, Inc. (CADL)
CIK: 0001841387
Period of Report: 2021-07-26

Reporting Person: Tak Paul Peter (Director, President & CEO)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$1.55	2030-10-09	Common Stock (296144)		Direct
Stock Option (Right to Buy)	$1.55	2030-10-09	Common Stock (1776868)		Direct

Footnotes

F1: This option shall vest (if at all) if a specified stock price following the Issuer's initial public offering is obtained on or prior to September 12, 2023.

F2: 25% of this option vested and became exercisable on October 10, 2020, with a remaining 25% vesting on September 14, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.